RxDoctor Payments Data

Susana Bell

Nurse Practitioner · Bakersfield, CANPI 1770605008

Payments from drug & device makers

$14,646in general payments, 2019–2025

Across 679 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Johnson & Johnson$1K
  • Exelixis Inc.$1K
  • Daiichi Sankyo Inc.$967
  • AstraZeneca$666
  • Seagen Inc.$661
  • plus $9K from 53 others

What the payments were for

  • Food & beverage$13,81394%
  • Education$8336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK41$1,204
Johnson & Johnson72$1,202
Exelixis Inc.41$1,004
Daiichi Sankyo Inc.55$967
AstraZeneca(2 entities)31$666
Seagen Inc.27$661
Sobi, Inc28$587
Astellas Pharma US Inc22$585
Takeda Pharmaceuticals U.S.A., Inc.21$534
Lilly USA, LLC19$487
Amgen18$434
Pfizer24$405
Novartis21$405
Genentech USA, Inc.19$357
Stemline Therapeutics Inc.13$338
Blueprint Medicines Corporation12$309
E.r. Squibb & Sons, L.L.C.16$295
Pharmacyclics LLC, An Abbvie Company20$292
Regeneron Healthcare Solutions, Inc.9$265
Pharmaessentia USA Corporation9$243
Bristol Myers Squibb12$234
Sanofi10$233
Incyte Corporation12$227
Merck11$223
Eisai Inc.11$206
Bayer6$192
Sun Pharmaceutical Industries Inc.8$182
AbbVie9$168
Gilead7$159
Jazz Pharmaceuticals Inc.7$157
Genmab U.S., Inc.5$121
Caris MPI, Inc.3$100
AVEO Pharmaceuticals, Inc.3$97
Rigel Pharmaceuticals, Inc.4$84
Beigene USA, Inc.4$78
Puma Biotechnology, Inc.4$74
AMAG Pharmaceuticals, Inc.3$72
Array Biopharma Inc8$68
Deciphera Pharmaceuticals Inc.3$66
EMD Serono, Inc.3$62
Geron Corporation2$60
Karyopharm Therapeutics Inc.2$55
Recordati_rare_diseases_inc.2$46
Morphosys, US Inc.2$45
Pharmacosmos Therapeutics Inc.2$44
Kyowa Kirin, Inc.2$39
Dova Pharmaceuticals2$38
Syndax Pharmaceuticals, Inc.2$33
Cumberland Pharmaceuticals, Inc.1$30
Boehringer Ingelheim2$30
Fennec Pharmaceuticals, Inc.1$25
Myriad Genetic Laboratories, Inc.1$25
Dendreon Pharmaceuticals LLC1$23
ADC Therapeutics America, Inc.1$22
Mirati Therapeutics, Inc.1$21
Apellis Pharmaceuticals, Inc.1$19
Blue Earth Diagnostics1$17
Aadi Bioscience, Inc.1$17
Ipsen Biopharmaceuticals, Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,646 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$132,863
Medicare patients
361
Services billed
1,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib15$210,714
Prochlorperazine Maleate46$1,020
Ondansetron Hcl25$799
Ondansetron OdtOndansetron24$737
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$578
Letrozole43$415
Potassium Chloride17$400
Anastrozole26$383
Gabapentin26$205
Lorazepam12$85
Levothyroxine Sodium12$72
Zolpidem Tartrate13$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$487$210,71415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →